{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:07:35Z","timestamp":1790654855850,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.leukres.2020.106356","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:04:53Z","timestamp":1589151893000},"page":"106356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-1307","authenticated-orcid":false,"given":"Leonard","family":"Naymagon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.leukres.2020.106356_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"6293","key":"10.1016\/j.leukres.2020.106356_bib0010","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/347558a0","article-title":"The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus","volume":"347","author":"de The","year":"1990","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.leukres.2020.106356_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2020.106356_bib0020","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","article-title":"Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience","volume":"115","author":"Ades","year":"2010","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.leukres.2020.106356_bib0025","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","article-title":"Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome","volume":"115","author":"Sanz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106356_bib0030","doi-asserted-by":"crossref","first-page":"e304","DOI":"10.1038\/bcj.2015.25","article-title":"Acute promyelocytic leukemia: where did we start, where are we now, and the future","volume":"5","author":"Coombs","year":"2015","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.leukres.2020.106356_bib0035","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2020.106356_bib0040","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2016-10-747170","article-title":"Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era","volume":"129","author":"Mantha","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2020.106356_bib0045","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2011.78","article-title":"Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry","volume":"25","author":"Lehmann","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2020.106356_bib0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.23158","article-title":"Bleeding and thrombosis in acute promyelocytic leukemia","volume":"87","author":"Choudhry","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3324\/haematol.2011.046490","article-title":"Treatment advances have not improved the early death rate in acute promyelocytic leukemia","volume":"97","author":"McClellan","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2020.106356_bib0060","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.clml.2018.11.004","article-title":"Real-life outcomes on acute promyelocytic leukemia in Brazil - early deaths are still a problem","volume":"19","author":"Silva","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.leukres.2020.106356_bib0065","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-04-346437","article-title":"Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid","volume":"118","author":"Park","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2020.106356_bib0070","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1073\/pnas.0915006107","article-title":"PML\/RARalpha fusion protein transactivates the tissue factor promoter through a GAGC-containing element without direct DNA association","volume":"107","author":"Yan","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"13","key":"10.1016\/j.leukres.2020.106356_bib0075","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJM199904013401303","article-title":"Annexin II and bleeding in acute promyelocytic leukemia","volume":"340","author":"Menell","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2020.106356_bib0080","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajh.2830330204","article-title":"Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders","volume":"33","author":"Takahashi","year":"1990","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106356_bib0085","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.leu.2401448","article-title":"Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents","volume":"13","author":"Zhu","year":"1999","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.leukres.2020.106356_bib0090","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2016-09-739334","article-title":"Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia","volume":"129","author":"Cao","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106356_bib0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.1989.tb06311.x","article-title":"The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination","volume":"71","author":"Bennett","year":"1989","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1988.tb02432.x","article-title":"Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia","volume":"70","author":"Avvisati","year":"1988","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"issue":"11","key":"10.1016\/j.leukres.2020.106356_bib0110","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood.V75.11.2112.2112","article-title":"Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients","volume":"75","author":"Rodeghiero","year":"1990","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2020.106356_bib0115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2004.11.001","article-title":"Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients","volume":"116","author":"Dally","year":"2005","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.leukres.2020.106356_bib0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-0609.2006.00803.x","article-title":"Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome","volume":"78","author":"Yanada","year":"2007","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2020.106356_bib0125","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3324\/haematol.2009.017962","article-title":"Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation","volume":"95","author":"Breccia","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2020.106356_bib0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1600-0609.2011.01747.x","article-title":"Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia","volume":"88","author":"Chang","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0135","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12032-013-0478-y","article-title":"International Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation &\/= 6: a new predictor of hemorrhagic early death in acute promyelocytic leukemia","volume":"30","author":"Mitrovic","year":"2013","journal-title":"Med. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2020.106356_bib0140","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00277-017-3042-6","article-title":"Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy","volume":"96","author":"Abla","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2020.106356_bib0145","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.2147\/OTT.S144438","article-title":"Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia","volume":"10","author":"Song","year":"2017","journal-title":"Onco. Ther."},{"key":"10.1016\/j.leukres.2020.106356_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2019.102351","article-title":"Factors affecting thrombohemorrhagic early death in patients with acute promyelocytic leukemia treated with arsenic trioxide alone","volume":"79","author":"Hou","year":"2019","journal-title":"Blood Cells Mol. Dis."},{"issue":"10","key":"10.1016\/j.leukres.2020.106356_bib0155","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/10428194.2019.1581187","article-title":"Predictors of early hemorrhage in acute promyelocytic leukemia","volume":"60","author":"Naymagon","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0160","first-page":"23","article-title":"Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia","volume":"3","author":"Ventura","year":"1989","journal-title":"Hematol. Pathol."},{"issue":"4","key":"10.1016\/j.leukres.2020.106356_bib0165","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<209::AID-HON615>3.0.CO;2-S","article-title":"Coagulation patterns of disseminated intravascular coagulation in acute promyelocytic leukemia","volume":"15","author":"Higuchi","year":"1997","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2020.106356_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.leukres.2010.05.022","article-title":"Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1998.16.1.78","article-title":"Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group","volume":"16","author":"Asou","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2020.106356_bib0180","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1200\/JOP.18.00328","article-title":"Treatment of acute promyelocytic leukemia in adults","volume":"14","author":"Osman","year":"2018","journal-title":"J. Oncol. Pract."},{"issue":"10","key":"10.1016\/j.leukres.2020.106356_bib0185","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1182\/blood-2017-01-757930","article-title":"Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial","volume":"130","author":"Uhl","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2020.106356_bib0190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2020.106356_bib0195","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2020.106356_bib0200","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V92.8.2712","article-title":"Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group","volume":"92","author":"De Botton","year":"1998","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.leukres.2020.106356_bib0205","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428190009060334","article-title":"Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia","volume":"38","author":"Che-Pin","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.leukres.2020.106356_bib0210","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1538-7836.2004.00787.x","article-title":"Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia","volume":"2","author":"Tallman","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.leukres.2020.106356_bib0215","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.thromres.2018.01.041","article-title":"Mechanisms and management of coagulopathy in acute promyelocytic leukemia","volume":"164","author":"David","year":"2018","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.leukres.2020.106356_bib0220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1365-2141.2000.01936.x","article-title":"Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia","volume":"108","author":"Di Bona","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2020.106356_bib0225","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.leukres.2013.05.007","article-title":"Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death","volume":"37","author":"Altman","year":"2013","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.leukres.2020.106356_bib0230","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.leukres.2014.06.011","article-title":"Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States","volume":"38","author":"Rashidi","year":"2014","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/asheducation-2016.1.10","article-title":"Acute promyelocytic leukemia: preventing early complications and late toxicities","volume":"2016","author":"Abedin","year":"2016","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"13","key":"10.1016\/j.leukres.2020.106356_bib0240","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2020.106356_bib0245","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106356_bib0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106174","article-title":"Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction","volume":"83","author":"Hambley","year":"2019","journal-title":"Leuk. Res."},{"issue":"25","key":"10.1016\/j.leukres.2020.106356_bib0255","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2009-07-216457","article-title":"How I treat acute promyelocytic leukemia","volume":"114","author":"Tallman","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2020.106356_bib0260","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2052-0492-2-15","article-title":"Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines","volume":"2","author":"Wada","year":"2014","journal-title":"J. Intensive Care"},{"issue":"20","key":"10.1016\/j.leukres.2020.106356_bib0270","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.leukres.2020.106356_bib0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000205321","article-title":"Acute promyelocytic leukemia: a 5-year experience with new antileukemic agents and a new approach to preventing fatal hemorrhage","volume":"82","author":"Feldman","year":"1989","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12185-013-1463-0","article-title":"Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin","volume":"100","author":"Ikezoe","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0285","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.leukres.2020.106356_bib0290","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.leukres.2012.08.012","article-title":"Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation","volume":"36","author":"Ikezoe","year":"2012","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2169\/internalmedicine.52.7978","article-title":"Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution","volume":"52","author":"Kawano","year":"2013","journal-title":"Intern. Med."},{"issue":"5","key":"10.1016\/j.leukres.2020.106356_bib0300","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.thromres.2014.02.025","article-title":"Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort","volume":"133","author":"Matsushita","year":"2014","journal-title":"Thromb. Res."},{"issue":"8655","key":"10.1016\/j.leukres.2020.106356_bib0305","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0140-6736(89)90181-5","article-title":"Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia","volume":"2","author":"Avvisati","year":"1989","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.leukres.2020.106356_bib0310","doi-asserted-by":"crossref","first-page":"873","DOI":"10.7326\/0003-4819-105-6-873","article-title":"Epsilon-aminocaproic acid in the treatment of patients with acute promyelocytic leukemia and acquired alpha-2-plasmin inhibitor deficiency","volume":"105","author":"Schwartz","year":"1986","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.leukres.2020.106356_bib0315","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/hon.867","article-title":"Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients","volume":"26","author":"Wassenaar","year":"2008","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2020.106356_bib0320","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.bmt.1705670","article-title":"The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review","volume":"39","author":"Franchini","year":"2007","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.leukres.2020.106356_bib0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1600-0609.2004.00237.x","article-title":"Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia","volume":"72","author":"Zver","year":"2004","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2020.106356_bib0330","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ajh.20713","article-title":"Use of Novoseven for arsenic trioxide-induced bleeding in PML","volume":"81","author":"Alimoghaddam","year":"2006","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0335","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/10428194.2011.605189","article-title":"Cerebral hemorrhage treated with NovoSeven in acute promyelocytic leukemia","volume":"53","author":"Nosari","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2020.106356_bib0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.10.015","article-title":"Efficacy of recombinant factor VIIa for severe bleeding complicated by platelet transfusion refractoriness in patients with hematologic malignancies","volume":"160","author":"Chu","year":"2017","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.leukres.2020.106356_bib0345","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-154-8-201104190-00004","article-title":"Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications","volume":"154","author":"Yank","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.leukres.2020.106356_bib0350","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/SLA.0b013e318176c4ec","article-title":"Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials","volume":"248","author":"Hsia","year":"2008","journal-title":"Ann. Surg."},{"issue":"11","key":"10.1016\/j.leukres.2020.106356_bib0355","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00277-017-3096-5","article-title":"Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia","volume":"96","author":"Lou","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2020.106356_bib0360","first-page":"1","article-title":"An effective early death scoring system for predicting early death risk in de novo acute promyelocytic leukemia","author":"Cai","year":"2020","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:57Z","timestamp":1758934797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":72,"alternative-id":["S0145212620300618"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106356","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106356"}}